Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A First-in-Human, Phase 1 Study to Assess the Pharmacodynamic Properties of Single-Dose Iptacopan (CLNP023X2101)

Robert Schmouder, Guido Junge, Prasanna Kumar Nidamarthy, Kenneth Kulmatycki

Blood (2023) 142 (Supplement 1): 4096.

https://doi.org/10.1182/blood-2023-179655

Published: 2023

Journal Articles

A Phase 1 Study to Evaluate the Pharmacokinetics of Single High Doses of Iptacopan

Robert Schmouder, Noemi Kaetterer, Kenneth Kulmatycki, Prasanna Kumar Nidamarthy

Blood (2023) 142 (Supplement 1): 2723.

https://doi.org/10.1182/blood-2023-179012

Published: 2023

Journal Articles

A Phase 1 Study to Assess the Effect of Supratherapeutic Doses of Iptacopan on Cardiac Conduction Parameters and Safety

Robert Schmouder, Noemi Kaetterer, Kenneth Kulmatycki, Prasanna Kumar Nidamarthy

Blood (2023) 142 (Supplement 1): 5644.

https://doi.org/10.1182/blood-2023-179648

Published: 2023

Journal Articles

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Timothy P. Hughes, MD, Eduardo Ciliao Munhoz, MD, Alaa Elhaddad, MD PhD, Ong Tee Chuan, MD, Kudrat Abdulkadyrov, MD, Jake Shortt, MD, Hang Quach, MD FRACP, FRCPA, MBBS, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Luis Meillon, MD, Lee-Yung Shih, MD Professor, Anna G. Turkina, MD PhD, Jonathan Hwang, PharmD, MBA, Prasanna Kumar Nidamarthy, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, PhD MD

Blood (2014) 124 (21): 4542.

https://doi.org/10.1182/blood.V124.21.4542.4542

Published: 2014

Journal Articles

Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial

Jorge E. Cortes, MD, Carmino Antonio De Souza, PhD, Jose Luis Lopez, MD, Manuel Ayala, MD, Eduardo Bullorsky, Xiaojun Huang, Sandip Shah, K. Govind Babu, Tomasz Sacha, MD, Israel Bendit, Zhizhou Liang, Tina Owugah, Prasanna Kumar Nidamarthy, Tomasz Szczudlo, Carmen Piccolo, MD, Philipp D. le Coutre, MD

Blood (2013) 122 (21): 95.

https://doi.org/10.1182/blood.V122.21.95.95

Published: 2013

NARROW

A First-in-Human, Phase 1 Study to Assess the Pharmacodynamic Properties of Single-Dose Iptacopan (CLNP023X2101)

A Phase 1 Study to Evaluate the Pharmacokinetics of Single High Doses of Iptacopan

A Phase 1 Study to Assess the Effect of Supratherapeutic Doses of Iptacopan on Cardiac Conduction Parameters and Safety

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial

Email alerts

ASH Publications

American Society of Hematology

A First-in-Human, Phase 1 Study to Assess the Pharmacodynamic Properties of Single-Dose Iptacopan (CLNP023X2101)

A Phase 1 Study to Evaluate the Pharmacokinetics of Single High Doses of Iptacopan

A Phase 1 Study to Assess the Effect of Supratherapeutic Doses of Iptacopan on Cardiac Conduction Parameters and Safety

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only